Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

Phase 2

Active, not recruiting

Conditions: Spinal Muscular Atrophy (SMA)

Interventions: Drug: Placebo
Drug: RO7204239
Drug: Risdiplam

First Posted Date: 2021-11-10

Last Posted Date: 2025-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 259

Registration Number: NCT05115110

Locations: 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇧🇪
Chr de La Citadelle, Liège, Belgium
🇵🇹
Hospital de Santa Maria, Lisboa, Portugal

and more 32 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: RO7247669 600 mg
Drug: RO7247669 2100 mg
Drug: Atezolizumab
Drug: Nivolumab
Drug: Ipilimumab
Drug: Tiragolumab

First Posted Date: 2021-11-10

Last Posted Date: 2024-10-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 110

Registration Number: NCT05116202

Locations: 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇺🇸
The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
🇮🇹
Ospedale S.Maria della Misericordia, Perugia, Umbria, Italy

and more 18 locations

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Atezolizumab
Drug: Pemetrexed
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Enzalutamide

First Posted Date: 2021-11-09

Last Posted Date: 2025-04-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT05112965

Locations: 🇨🇳
Changchun Cancer Hospital, Changchun, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, China
🇨🇳
Union Hospital of Tongji Medical College, Dept. of Cancer Center, Wuhan, Hubei, China

and more 16 locations

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Small-Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Lurbinectedin
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2021-10-25

Last Posted Date: 2025-04-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 660

Registration Number: NCT05091567

Locations: 🇹🇷
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Turkey
🇹🇷
Ba?c?lar Medipol Mega Üniversite Hastanesi, Istanbul, Turkey
🇹🇷
Istanbul Uni Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey

and more 90 locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

Recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Mosunetuzumab
Drug: Tocilizumab
Drug: Venetoclax

First Posted Date: 2021-10-25

Last Posted Date: 2025-05-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 137

Registration Number: NCT05091424

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Uni of Texas - Md Anderson Cancer Center, Houston, Texas, United States

and more 19 locations

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Crovalimab
Drug: Placebo

First Posted Date: 2021-10-13

Last Posted Date: 2025-03-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 90

Registration Number: NCT05075824

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
Mississippi Center for Advanced Medicine, Madison, Mississippi, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 25 locations

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study

Terminated

Conditions: Long COVID
COVID-19

First Posted Date: 2021-09-28

Last Posted Date: 2023-07-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 72

Registration Number: NCT05059080

Locations: 🇦🇷
Instituto Ave Pulmo, Mar Del Plata, Argentina
🇧🇷
Chronos Pesquisa Clinica, Taguatinga, DF, Brazil
🇺🇦
Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine

and more 32 locations

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2021-09-17

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05047250

Locations: 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing City, China
🇨🇳
Beijing Tiantan Hospital,Capital Medical University, Beijing, China
🇨🇳
Beijing Chest Hospital, Beijing, China

and more 24 locations

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Phase 2

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Placebo
Drug: Obinutuzumab
Drug: Mycophenolate Mofetil
Drug: Acetaminophen/paracetamol
Drug: Diphenhydramine hydrochloride (HCl)
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2021-09-09

Last Posted Date: 2025-05-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT05039619

Locations: 🇺🇸
Loma Linda University health, Loma Linda, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Anchutz Medical Campus, Aurora, Colorado, United States

and more 39 locations

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Rectal Neoplasms
Rectal Cancer

Interventions: Radiation: Radiotherapy
Drug: Capecitabine
Drug: Fluorouracil
Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2021-08-17

Last Posted Date: 2025-04-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 58

Registration Number: NCT05009069

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy